Charles Schwab
ANRO icon

Charles Schwab’s Alto Neuroscience ANRO Stock Holding History

Charles Schwab’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Sell
17,018
-46
-0.3% -$853 ﹤0.01% 3190
2025
Q4 		$304K Buy
+17,064
New +$215K ﹤0.01% 3276
2025
Q3 		– Sell
-115,263
Closed -$254K – 3557
2025
Q2 		$254K Sell
115,263
-35,158
-23% -$83.7K ﹤0.01% 3351
2025
Q1 		$325K Sell
150,421
-4,410
-3% -$15.8K ﹤0.01% 3186
2024
Q4 		$655K Sell
154,831
-32,137
-17% -$201K ﹤0.01% 3059
2024
Q3 		$2.14M Buy
186,968
+120,779
+182% +$1.48M ﹤0.01% 2692
2024
Q2 		$708K Buy
66,189
+21,158
+47% +$275K ﹤0.01% 3051
2024
Q1 		$691K Buy
+45,031
New +$705K ﹤0.01% 2908

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's ANRO Position: Q1 2026 in Review

Charles Schwab reduced its Alto Neuroscience (ANRO) stake by 0.27% in Q1 2026, selling an estimated $853 and leaving 17,018 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #3190.

Charles Schwab first reported a position in ANRO in Q1 2024 and has held it in 8 quarters since. The position peaked at $2.14M in Q3 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Charles Schwab held 17,018 shares of Alto Neuroscience worth $383K as of Q1 2026.
  • Charles Schwab sold 46 Alto Neuroscience shares in Q1 2026, an estimated $853.
  • Alto Neuroscience made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3190 holding.
  • Charles Schwab first reported a position in Alto Neuroscience in Q1 2024 and has held it in 8 quarters since.
  • Charles Schwab's Alto Neuroscience position peaked at $2.14M in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.